Diagnostic Value of TROP2 Expression in Papillary Thyroid Carcinoma.
Adenoma
/ diagnosis
Adolescent
Adult
Aged
Antigens, Neoplasm
/ metabolism
Biomarkers, Tumor
/ metabolism
Cell Adhesion Molecules
/ metabolism
Child
Diagnosis, Differential
Female
Humans
Immunohistochemistry
Male
Middle Aged
Predictive Value of Tests
Sensitivity and Specificity
Thyroid Cancer, Papillary
/ diagnosis
Thyroid Neoplasms
/ diagnosis
Young Adult
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
08
07
2020
accepted:
14
10
2020
pubmed:
3
12
2020
medline:
4
11
2021
entrez:
2
12
2020
Statut:
ppublish
Résumé
Papillary thyroid carcinoma (PTC) represents the most common primary malignant thyroid lesion in all age groups. As diagnosis of PTC could be challenging in some cases and borderline nuclear features could be seen in some benign mimickers, several immunohistochemical markers are proposed to be helpful for making the correct diagnosis. In this study the authors investigated the diagnostic value of transmembrane glycoprotein (TROP2) for differentiating PTC from other thyroid follicular lesions. A total of 155 total thyroidectomy specimens including 84 cases of PTC and 71 cases of non-PTC were investigated. Among non-PTC group, 45 cases were follicular neoplasms and 26 cases were Hashimoto thyroiditis. TROP2 expression was observed in 82 of 84 cases of PTC group. In contrast only 5 cases of non-PTC group, all from Hashimoto thyroiditis specimens, showed positive expression. The sensitivity, specificity, positive predictive value, and negative predictive value of TROP2 for diagnosis of PTC was 98%, 93%, 94%, and 97%, respectively. The authors concluded that high sensitivity and specificity of TROP2 as well as its uniform negative reaction in follicular adenoma and carcinoma makes it a valuable immunohistochemical marker for diagnosis of PTC.
Identifiants
pubmed: 33264108
pii: 00129039-202103000-00007
doi: 10.1097/PAI.0000000000000886
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Cell Adhesion Molecules
0
TACSTD2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
218-222Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Jun P, Chow LC, Jeffrey RB. The sonographic features of papillary thyroid carcinomas: pictorial essay. Ultrasound Q. 2005;21:39–45.
Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130:736–744.
Arcolia V, Journe F, Renaud F. Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer. Oncol Lett. 2017;14:4183–4189.
Nesreen HH, Manal SZ, Mohamed AM. Diagnostic utility of trophoblastic cell surface antigen 2 immunohistochemical expression in papillary thyroid carcinoma. J Pathol Nepal. 2018;8:1235–1243.
Ohmachi T, Tanaka F, Mimori K, et al. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006;12:3057–3063.
Fong D, Spizzo G, Gostner JM. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2008;21:186–191.
Trerotola M, Li J, Alberti S, et al. Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis. J Cell Physiol. 2012;227:3670–3677.
Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290–1295.
Li X, Teng S, Zhang Y, et al. TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT. Oncotarget. 2017;8:47052–47063.
Xu N, Zhang Z, Zhu J, et al. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma. Int J Exp Pathol. 2016;97:150–158.
Addati T, Achille G, Centrone M, et al. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study. Cytopathology. 2015;26:303–311.
Bychkov A, Sampatanukul P, Shuangshoti S, et al. TROP2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma. Pathology. 2016;48:425–433.
Liu H, Shi J, Lin F. The potential diagnostic utility of TROP-2 in thyroid neoplasms. Appl Immunohistochem Mol Morphol. 2016;25:525–533.
Simms A, Jacob RP, Cohen C, et al. TROP-2 expression in papillary thyroid carcinoma: potential diagnostic utility. Diagn Cytopathol. 2016;44:26–31.
Fang YJ, Lu ZH, Wang GQ, et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009;24:875–884.
Stepan LP, Trueblood ES, Hale K, et al. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications. J Histochem Cytochem. 2011;59:701–710.
Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222–233.
Murtezaoglu AR, Gucer H. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19. Pol J Pathol. 2017;68:1–10.
Gaber Abdou A, Shabaan M, Abdallha R, et al. Diagnostic value of TROP-2 and CK19 expression in papillary thyroid carcinoma in both surgical and cytological specimens. Clin Pathol. 2019;12:1–16.
Bussolati G, Gugliotta P, Volante M, et al. Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology. 1997;31:400–407.
Cyniak-Magierska A, Wojciechowska-Durczynska K, Krawczyk-Rusiecka K, et al. Assessment of RET/PTC1 and RET/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto’s thyroiditis. Thyroid Res. 2011;4:5.
Khatami F, Tavangar SM. A review of driver genetic alterations in thyroid cancers. Iran J Pathol. 2018;13:125–135.
de Matos PS, Ferreira AP, de Oliveira Facuri F, et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47:391–401.
Nasr MR, Mukhopadhyay S, Zhang S, et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006;19:1631–1637.
Rorive S, Eddafali B, Fernandez S, et al. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol. 2002;15:1294–1301.
Xin Y, Guan D, Meng K, et al. Diagnostic accuracy of CK-19, galectin-3 and HBME-1 on papillary thyroid carcinoma: a meta-analysis. Int J Clin Exp Pathol. 2017;10:8130–8140.
Song Q, Wang D, Lou Y, et al. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the north eastern region of China. Diagn Pathol. 2011;6:126.
Barroeta JE, Baloch ZW, Lal P, et al. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol. 2006;17:225–234.
Scognamiglio T, Hyjek E, Kao J, et al. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006;126:700–708.
Sanuvada R, Nandyala R, Chowhan AK, et al. Value of cytokeratin-19, Hector Battifora mesothelial-1 and galectin-3 immunostaining in the diagnosis of thyroid neoplasms. J Lab Physicians. 2018;10:200–207.